Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Vion (NASDQ:VION) said FDA lifted a clinical hold on a Phase III trial (Study CLI-037) of Cloretazine ( VNP40101M) plus cytarabine to treat
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury